A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC
BeOne Medicines
UroGen Pharma Ltd.
UroGen Pharma Ltd.
CG Oncology, Inc.
EMD Serono
Sichuan Baili Pharmaceutical Co., Ltd.
Incyte Corporation
UNICANCER
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
UroGen Pharma Ltd.
UroGen Pharma Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd.
Nottingham University Hospitals NHS Trust
UroGen Pharma Ltd.
Pfizer
RemeGen Co., Ltd.
National Cancer Institute (NCI)
Eli Lilly and Company
Hoffmann-La Roche
UroGen Pharma Ltd.
Shanghai Junshi Bioscience Co., Ltd.
UroGen Pharma Ltd.
Samyang Biopharmaceuticals Corporation
Endo Pharmaceuticals
Asan Medical Center
Asan Medical Center
Bristol-Myers Squibb
Association of Urologic Oncology (AUO)